Veradermics stock context for investors

Veradermics (MANE) has drawn investor attention after recent trading, with the share price closing at $47.35 and short term returns of 5.0% over the past day and 12.3% over the past week.

The recent 1 day share price return of 5.0% and 7 day share price return of 12.3% sit within a broader year to date share price return of 25.4%. This suggests that momentum has been building rather than fading as investors reassess Veradermics' pipeline and risk profile.

If this kind of move has you looking beyond a single name, it could be a good moment to scan our screener of 31 healthcare AI stocks as potential next ideas.

With MANE trading at $47.35 against an analyst price target near $78 and an indicated intrinsic discount of about 52%, you have to ask: is Veradermics still undervalued, or is the market already pricing in future growth?

DCF valuation: SWS fair value signals upside against the current price

Our DCF model currently estimates Veradermics' fair value at about $98.85 per share, versus the last close of $47.35, implying a wide gap between modelled value and market price.

The SWS DCF model projects future cash flows for the business and then discounts them back to today using a required return. This produces a single fair value estimate in dollar terms. That $98.85 output is therefore a function of long term cash generation assumptions rather than near term share price moves.

For a company like Veradermics, which reports no revenue and a net loss of $61.641m, a DCF framework helps investors think in terms of potential future cash flows from its dermatology pipeline rather than current income statement figures alone. At the same time, the company has less than one year of cash runway and is forecast to remain unprofitable for at least three years. As a result, the gap between $47.35 and $98.85 relies heavily on long dated projections.

Result: DCF Fair value of $98.85 (UNDERVALUED)

However, with no current revenue, a net loss of $61.641m, and less than one year of cash runway, funding risk and clinical setbacks could quickly challenge this upside story.

Key qualitative checks investors are weighing

Alongside the SWS DCF output, several fundamentals frame how you might think about Veradermics today.

• The company currently reports no revenue and a net loss of $61.641m, and analysts expect it to remain unprofitable over the next 3 years with no revenue forecast for next year.
• Equity is negative, which feeds through to a negative Return on Equity of 411.16% and a P/B ratio of 18x versus 2.1x for the wider US pharmaceuticals group and 3.5x for peers. That kind of gap highlights meaningful valuation risk if expectations change.
• Veradermics is assessed as having less than one year of cash runway, with 100% of liabilities coming from higher risk funding sources. This keeps financing and dilution risk firmly on the table.
• The management team is relatively new with an average tenure of 0.7 years, while the board looks more seasoned at 4.5 years on average and 86% independence. This is supported by what appears to be balanced board refreshment over the last 3 years.
• CEO compensation of $8.46m is above the $5.28m average for similar sized US companies and has increased while the company is loss making, something many investors watch closely when they think about alignment.

None of these points answer the central question for you, which is whether Veradermics' dermatology pipeline and risk profile justify its current valuation or call for extra caution.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Veradermics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of risks and potential rewards feels finely balanced, it may be worth taking a closer look now and forming your own view with 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If Veradermics has you thinking more broadly about where to put your capital next, it is worth lining up a few fresh ideas before the market moves again.

• Target value first and hunt for companies that look mispriced on quality and fundamentals through our 47 high quality undervalued stocks sourced directly from the Simply Wall St screener.
• Prioritise resilience by scanning 77 resilient stocks with low risk scores so you can focus on businesses with lower risk scores that might better fit a steadier approach.
• Get ahead of the crowd by checking our screener containing 24 high quality undiscovered gems and see which under the radar names already stand out on core financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.